Beam Therapeutics Inc

Beam Therapeutics Inc. sees a surge in stock value after the FDA grants orphan drug status to one of its gene-editing therapies, a move that could streamline the path to market for groundbreaking treatments.

Beam Therapeutics Inc. reported a larger-than-expected loss in its first-quarter 2025 financial results, but remains committed to advancing its clinical programs and achieving long-term stability.

Beam Therapeutics Inc. reported a $109.27 million loss in Q1 2025, exceeding last year’s figures and analyst expectations, but projects financial stability through 2028.